ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2773

Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier

Asmir Vodencarevic 1, David Simon 2, Fabian Hartmann 2, Michaela Reiser 2, Axel Hueber 2, Koray Tascilar 3, Arnd Kleyer 4, Marcus Zimmermann-Rittereiser 1 and Georg Schett5, 1Siemens Healthcare GmbH, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 4Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 5Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: data analysis and biologic drugs, patient outcomes, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T092: RA – Treatments IV: Novel Therapy & Predicting Response (2768–2773)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Tapering or stopping conventional and biologic DMARDs in patients with rheumatoid arthritis (RA) in stable  remission may be feasible in a subset of patients [1]. However, the prediction of the patients’ individual flare risk remains challenging. Hence, reliable models based on machine learning algorithms could be helpful tools for flare prediction [2]. Therefore, the purpose of this study was to investigate the feasibility of building a predictive model for estimating the individual flare probability in RA patients tapering biologic DMARDs using (1) a small cohort of patients, (2) high quality data and (3) a combination of different machine learning models.

Methods: Longitudinal clinical data of RA patients on biologic DMARDs from the phase-3, multicentre, randomised, open, prospective, controlled, parallel-group RETRO study (EudraCT number 2009-015740-42) was used. In order to exploit the flexibility obtained by combining different machine learning models a stacking meta-classifier is used [3]. At first, four models are trained: log. regression, random forest, k-NN and naïve Bayes which output the flare probability at each patient visit. These probabilities are the input features for the stacking logistic regression meta-classifier. The final prediction performance expressed as the AUROC is estimated using the nested cross-validation [4]. The importance of single predictors was estimated using the permutation importance approach [5].

Results: Data of 41 RETRO study patients with 135 follow-ups were used. The measured AUROC of the model was 0.802 (95%CI 0.717 – 0.887, Figure 1). A steadily growing model performance was observed with the increasing size of the available data (Figure 2). Of the ten most important variables for the machine learning model, the dose percentage change of bDMARD, clinical disease activity (DAS28-ESR), disease duration and inflammatory markers such as ESR or CRP reached the highest significance (Figure 3).

Conclusion: It is possible to train a good predictive model for RA flare probability with small data of high quality using a flexible combination of different classifiers. These results confirm the feasibility of guided tapering based on machine learning models and show that such models could be a reliable flair risk assessment tool for physicians in the future.

References:

[1] Haschka J et al. Ann Rheum Dis 2016; 75:45-51
[2] Vodencarevic A et al. DATA 2018; 187-192
[3] Tang J et al. CRC Press 2015; 498-500
[4] Cawley GC et al. J Mach Learn Res 2010; 11:2079-2107
[5] Breiman L Mach Learn 2001; 45:5-32

Figure 1: AUROC curve for the predictive machine learning model

Figure 2: Learning curve of the stacking meta-classifier

Figure 3: Relative importance of clinical and demographic variables for the machine learning model
Dose Percentage Change: change in the percentage of full standard dose from its last value recorded within last 24 weeks; DAS28: Disease Activity Score 28; ESR: Erythrocyte Sedimentation Rate; CRP: C‐Reactive Protein; HAQ: Health Assessment Questionnaire


Disclosure: A. Vodencarevic, Siemens Healthcare GmbH, 1, 3, 4; D. Simon, None; F. Hartmann, None; M. Reiser, None; A. Hueber, None; K. Tascilar, None; A. Kleyer, None; M. Zimmermann-Rittereiser, Siemens Healthcare GmbH, 1, 3, 4; G. Schett, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, 8, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB, 5, BMS, Celgene, GSK, Lilly, Novartis, 2.

To cite this abstract in AMA style:

Vodencarevic A, Simon D, Hartmann F, Reiser M, Hueber A, Tascilar K, Kleyer A, Zimmermann-Rittereiser M, Schett G. Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/individually-tailored-predictions-of-flare-probability-for-rheumatoid-arthritis-patients-on-biologic-dmards-based-on-machine-learning-stacking-meta-classifier/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/individually-tailored-predictions-of-flare-probability-for-rheumatoid-arthritis-patients-on-biologic-dmards-based-on-machine-learning-stacking-meta-classifier/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology